Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05181709 · ClinicalTrials.gov registry record · Phase 1
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
A Phase 1 study of SARS-CoV-2, sponsored by Sean Liu.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT05181709 is a Phase 1 study of SARS-CoV-2 that has completed, run by Sean Liu. The registered enrollment target is 35 participants, below the 3,769-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05181709, a Phase 1 study of SARS-CoV-2, has completed, sponsored by Sean Liu.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations will be identical in composition and only differ in route of administration.
Conditions Studied
Interventions
- DRUG Sodium Chloride
- BIOLOGICAL NDV-HXP-S IN low dose
- BIOLOGICAL NDV-HXP-S IM low dose
- BIOLOGICAL NDV-HXP-S IN high dose
- BIOLOGICAL NDV-HXP-S IM high dose
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-02-09 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05181709
The ClinicalTrials.gov registry entry for NCT05181709 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,769-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The listed sponsor is Sean Liu, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 5 interventions - of which Sodium Chloride is the first listed.
NCT05181709 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05181709 about?
NCT05181709 is a clinical study titled "A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.". This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized...
What is the current status of trial NCT05181709?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2022-02-09. Estimated completion is 2024-04-19.
What conditions does trial NCT05181709 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT05181709?
The interventions under investigation include: Sodium Chloride (DRUG), NDV-HXP-S IN low dose (BIOLOGICAL), NDV-HXP-S IM low dose (BIOLOGICAL), NDV-HXP-S IN high dose (BIOLOGICAL), NDV-HXP-S IM high dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT05181709?
This trial is sponsored by Sean Liu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05181709 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
COMPLETED · Phase 1
-
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COMPLETED · Phase 1
-
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
COMPLETED · Phase 1
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.